Navigation Links
Jefferson researchers find nanoparticle shows promise in reducing radiation side effects

A gene responsible for the production of a protein called vasostatin may prove a promising new way of treating pancreatic cancer, suggests research published ahead of print in Gut.

Pancreatic cancer is the fifth leading cause of cancer deaths in the developed world, and is extremely difficult to treat. Only 3% of affected patients are still alive five years after diagnosis, a survival rate that has remained static for the past three decades.

Currently, the only viable treatment is surgery. Radiotherapy and chemotherapy have little impact on the disease.

The research team investigated the potential of the protein vasostatin to suppress the development of new blood vessels and pancreatic tumour cells both in test tubes and in mice with pancreatic cancer.

'Solid' tumours, such as pancreatic cancer, are heavily dependent on a rich blood supply to enable them to grow rapidly and spread throughout the body. This process is known as angiogenesis.

The protein gene was incorporated into a virus (adenovirus), so that it would be able to penetrate the cells, acting as a vector.

The test tube experiments showed that 72 hours after infection with the genetically modified virus, vasostatin was clearly active in the tissue. Tumour growth in the mice was also curbed, and when compared with mice which had not been infected with the virus, the difference between the two groups was highly significant.

The researchers then looked more closely at the pancreatic cells and the cell linings of the blood vessels (vascular endothelial cells).

They found that although vasostatin seemed to have little impact on the pancreatic cells, it blocked the formation of new blood vessels, effectively cutting off the supply of nutrients to the malignant cells. This effect was seen in both the test tube and animal experiments.

This type of gene therapy "may be a potent strategy to treat many malignant tumours, including pancreatic can cer, and represents a promising therapeutic option for malignancy with a poor prognosis," conclude the authors.


'"/>

Source:Thomas Jefferson University


Related biology news :

1. Jefferson Virologists Coax HIV Out of Hiding
2. Jefferson biologist coaxing human embryonic stem cells to make dopamine with simpler, faster method
3. Jefferson scientists identify gene defect leading to abnormal skin development and cancer
4. Jefferson researchers building a better rabies vaccine
5. Jefferson scientists identify gene mutation potentially involved in breast cancer initiation
6. Immune cell communication key to hunting viruses, Jefferson immunologists show
7. Jefferson researchers uncover new way nature turns genes on and off
8. Jefferson scientists find aging gene also protects against prostate cancer development
9. Jefferson scientists find high glucose before surgery raises risk of dangerous complications
10. Jefferson researchers discovery may change thinking on how viruses invade the brain
11. Elderly spinal cord injuries increase five-fold in 30 years, Jefferson neurosurgeons find
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/28/2016)... Sweden , April 28, 2016 First ... M (139.9), up 966% compared with the first quarter of 2015 ... profit totaled SEK 589.1 M (loss: 18.8) and the operating margin ... 7.12 (loss: 0.32) Cash flow from operations was SEK ... The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
(Date:4/15/2016)... CHICAGO , April 15, 2016  A ... companies make more accurate underwriting decisions in a ... offering timely, competitively priced and high-value life insurance ... health screenings. With Force Diagnostics, rapid ... and lifestyle data readings (blood pressure, weight, pulse, ...
(Date:3/31/2016)... 2016   LegacyXChange, ... "Company") LegacyXChange is excited to release its ... to be launched online site for trading 100% guaranteed ... will also provide potential shareholders a sense of the ... an industry that is notorious for fraud. The video ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... ... ... Parallel 6 , the leading software as a service (SaaS) provider ... Patient Encounter CONSULT module which enables both audio and video telemedicine communication between the ... the CONSULT module, patients and physicians can schedule a face to face virtual patient ...
(Date:6/27/2016)... PHILADELPHIA , June 27, 2016  Liquid ... today announced the funding of a Sponsored Research ... study circulating tumor cells (CTCs) from cancer patients.  ... changes in CTC levels correlate with clinical outcomes ... therapies. These data will then be employed to ...
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... the release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” ... and retention in this eBook by providing practical tips, tools, and strategies for ...
Breaking Biology Technology: